Dirk Thye

Dirk Thye (chief executive) discloses dealings in IRulya Therapeutics Inc. to SEC (Form 4). We count 8 filings; the first trade dates from 19 May 2022 and the latest from 10 December 2025.

The open-market record is one-sided, with 3 purchases worth €240k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 3 share grants and 1 option exercise.

A typical purchase (the median) is worth €91k. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 12 December 2025, the filings show a transaction in IRulya Therapeutics Inc. The last insider purchase was made public on 3 September 2024, 775 days ago. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.